pharmaceuticals
pharmaceuticals Articles
Pfizer is scheduled to report its fourth-quarter financial results before the markets open on Tuesday.
Published:
Last Updated:
Proteostasis Therapeutics expects to price more than 3 million shares in the range of $12 to $14 per share in an initial public offering is valued up to $62 million.
Published:
Last Updated:
More than 3 million PLx Pharma shares are expected to price in the range of $17 to $19 per share in an initial public offering valued up to about $83 million.
Published:
Last Updated:
Neos Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) regarding its secondary offering.
Published:
Last Updated:
Alere absolutely skyrocketed in Monday’s regular session following the announcement that it will be acquired by Abbott Laboratories.
Published:
Last Updated:
24/7 Wall St. has collected three big FDA decisions coming up in February and added some color, along with the trading range and price target.
Published:
Last Updated:
AbbVie reported mixed fourth-quarter financial results after the markets closed Thursday.
Published:
Last Updated:
AbbVie is scheduled to report its fourth-quarter financial results before the markets open Friday.
Published:
Last Updated:
Jefferies has four top biotech picks for 2016 that all have substantial upside and may provide investors with solid alpha for 2016.
Published:
Last Updated:
The January 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Published:
Last Updated:
Johnson & Johnson reported its fourth-quarter financial results before the markets opened on Tuesday.
Published:
Last Updated:
Johnson & Johnson is set to release its fourth-quarter financial results before the markets open Tuesday.
Published:
Last Updated:
Mapi Pharma expects to price more than 3 million shares in the range of $15 to $17 in an initial public offering valued up to more than $61 million.
Published:
Last Updated:
Agile Therapeutics fell in Friday’s session, despite the broad markets taking off, after the company announced the pricing for its secondary offering.
Published:
Last Updated:
PLx Pharma intends to price its more than 3 million shares in the range of $17 to $19 per share, for an IPO valued up to about $83 million.
Published:
Last Updated: